Plain-English translation of NCT07863986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study is looking for better ways to predict which patients with advanced prostate cancer will respond well to Lutetium-177 PSMA radioligand therapy (Pluvicto). Researchers will collect imaging scans, blood tests, and other medical information before and during treatment to identify patterns that show which patients benefit most from this medication. The goal is to create a tool that helps doctors predict treatment success for future patients.
Currently, only about half of patients treated with this medication see a significant drop in their cancer markers, but doctors don't have reliable tools to predict ahead of time who will respond. This study aims to fill that gap by combining imaging, blood work, and other data to create a predictive model that could help doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will be followed at a specialized nuclear medicine center where doctors will collect your imaging scans (PET and SPECT scans), blood work, and clinical information before and during your treatment with the medication. Some participants will enroll prospectively (starting fresh with the study) and provide ongoing data, while others may have their past medical records reviewed. The study involves completing standard cancer monitoring tests and scans you would likely receive anyway, with researchers analyzing this information to understand what predicts your response to treatment.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Lithuania